Ascletis Pharma Inc. announced positive topline results from the phase III open-label study (NCT06248008) evaluating denifanstat (ASC40), a first-in-class, once-daily oral small molecule fatty acid ...
- Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study - The exceptional efficacy of denifanstat ...
HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced positive topline results from the Phase III open-label study (NCT06248008) evaluating denifanstat ...
In a tit-for-tat move, Iran has said it now considers EU militaries to be terrorist organizations. The Iranian president has called for tensions with Washington to be resolved diplomatically. Iran has ...
Abstract: We develop an output feedback tracking controller for a class of underactuated nonlinear systems, specifically applied to a wafer handling robot in semiconductor manufacturing. The proposed ...
Abstract: In this paper, we propose a state-dependent switching controller for multiple-input multiple-output (MIMO) bilinear systems with constant delays in both the state and the input. The control ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results